Mankind Pharma Ltd

Mankind Pharma Ltd announced today, October 29, 2026, that CRISIL Ratings Limited (“CRISIL”) has reaffirmed and withdrawn credit ratings for several of the company’s instruments, as per Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Specifically, CRISIL reaffirmed the rating of “Crisil AA+/Stable” for Non-Convertible Debentures amounting to Rs 400 crore and another tranche of Non-Convertible Debentures amounting to Rs 2,100 crore, while withdrawing the “Crisil AA+/Stable” rating previously assigned to Non-Convertible Debentures totaling Rs 2,500 crore; additionally, CRISIL has withdrawn the “Crisil A1+” rating for Commercial Paper valued at Rs 1,500 crore, with the detailed rationale accessible via a link provided in the release and also on the company’s website at www.mankindpharma.com.

The key equity benchmarks ended near flat line on Tuesday, as investors remained cautious amid the NSE derivatives monthly expiry and the ongoing Q2 earnings season. The Nifty settled below the 22,750 mark, reflecting a lack of strong buying interest in frontline stocks. Media, realty and pharma shares advanced while private bank and IT stocks declined. As per provisional closing data, the S&P BSE Sensex declined 8.08 points or 0.01% to 73,598.67. The Nifty 50 index fell 3.45 points or 0.02% to 22,749.75. The broader market outperformed the frontline indices. The Nifty MidCap 150 Index advanced 1.01% and the Nifty SmallCap 250 Index rose 2.01%. The market breadth was strong. On the BSE, 2,938 shares rose and 1,381 shares fell. A total of 238 shares were unchanged. The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, fell 3.67% to 16.53. Initial Public Offer (IPO): EAAA India Alternatives received bids for 14,04,675 shares as against 52,99,684 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 0.27 times. The issue opened for bidding on 26 October 2026 and will close on 28 October 2026. The price band of the IPO is fixed between Rs 1,585 and 1,665 per share. An investor can bid for a minimum of 9 equity shares and multiples thereof. BLS Polymers received bids for 9,87,45,600 shares as against 1,19,00,000 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 8.30 times. The issue opened for bidding on 27 October 2026 and will close on 29 October 2026. The price band of the IPO is fixed between Rs 142 and 150 per share. An investor can bid for a minimum of 100 equity shares and multiples thereof. SFC Environmental Technologies received bids for 11,71,710 shares as against 1,41,59,744 shares on offer, according to stock exchange data at 15:30 IST on 27 October 2026. The issue was subscribed 0.08 times. The issue opened for bidding on 27 October 2026 and will close on 29 October 2026. The price band of the IPO is fixed between Rs 313 and 330 per share. An investor can bid for a minimum of 45 equity shares and multiples thereof. Buzzing Index; The Nifty Media index jumped 3.49% to 1,621.70. The index declined 5.47% in the past five trading sessions. Sun TV Network (up 10.94%), Prime Focus (up 9.22%), Saregama India (up 4.31%), PVR Inox (up 4.22%) and Tips Music (up 3.47%), Network 18 Media & Investments (up 2.85%), D B Corp (up 1.06%), Nazara Technologies (up 0.56%), Zee Entertainment Enterprises (up 0.26%) surged. Stocks in Spotlight: Mankind Pharma jumped 8.63% after reporting strong financial results for Q2 FY27, with revenue, EBITDA and net profit increasing year on year. The company's profit after tax rose 37.7% year on year to Rs 716 crore from Rs 520 crore. Sequentially, net profit increased 24.7% from Rs 574 crore in Q1 FY27. Revenue from operations increased 17.3% year on year to Rs 4,338 crore from Rs 3,697 crore. On a quarter-on-quarter basis, revenue grew 7.6% from Rs 4,031 crore. OneSource Specialty Pharma surged 13.64% after the company reported strong Q2 FY27 results, with revenue and adjusted net profit increasing year on year. The company's adjusted net profit rose 108.69% year on year to Rs 93.7 crore from Rs 44.9 crore in Q2 FY26. Sequentially, adjusted net profit increased 47.25% from Rs 63.7 crore in Q1 FY27. Revenue from operations increased 37.39% year on year to Rs 516.24 crore from Rs 375.76 crore. On a quarter-on-quarter basis, revenue rose 14.97% from Rs 449.02 crore in Q1 FY27. Aequs tumbled 9.85% after the company's consolidated net loss widened to Rs 52.39 crore in Q2 FY27 compared with net loss of Rs 20.59 crore in Q2 FY26. Revenue from operations soared 45.27% year-on-year (YoY) to Rs 409.07 crore in Q2 FY27, supported by growth across its aerospace and consumer businesses. Cipla fell 0.22% after the drug major's consolidated profit attributable to shareholders stood at Rs 878 crore in Q2 FY27, down 35% year on year from Rs 1,351 crore in Q2 FY26. Revenue from operations declined 2.44% year on year to Rs 7,404 crore from Rs 7,589 crore. Global Market: Dow futures rose 82 points, signalling a higher opening for US stocks. European indices declined on Tuesday as investors assessed geopolitical tensions in the Middle East, elevated crude oil prices and the outlook for global interest rates. Caution also prevailed ahead of major US technology earnings and key central bank policy decisions. Asian equities ended mixed on Tuesday, as the filing for artificial intelligence (AI) company Anthropic's planned initial public offering revived appetite for technology stocks ahead of a busy week of corporate earnings and central bank decisions. South Korea's economy grew 3.4% year on year in the third quarter of 2026, slowing from 3.7% in the previous quarter, preliminary data from the Bank of Korea showed on Tuesday. GDP expanded 1.0% quarter on quarter, accelerating from 0.6% in the April-June quarter. Semiconductor exports and investment in production equipment supported the expansion, although private consumption fell 0.2% quarter on quarter. Wall Street ended higher on Monday, 26 October 2026. The Dow Jones Industrial Average rose 146.42 points, or 0.28%, to 52,361.58. The S&P 500 gained 53.09 points, or 0.70%, to 7,676.77, while the Nasdaq Composite advanced 214.04 points, or 0.83%, to 26,169.38. The Philadelphia Semiconductor Index climbed 2.8%, marking its biggest one-day gain in a month, as chip-related shares led the recovery. The technology sector gained 1.5%, leading the S&P 500's 11 major sectors. Anthropic's IPO filing helped revive the AI trade by highlighting rapid revenue growth alongside the substantial costs and risks of developing advanced AI systems. The company's first-half 2026 net loss widened to $80.7 billion, largely because of a non-operating accounting item related to convertible bonds. Its operating loss narrowed to $693 million, while adjusted operating income turned positive at $1.62 billion, compared with a loss of $1.85 billion a year earlier. Revenue grew 1,368% year on year in the three months ended 30 June 2026. The filing also highlighted risks linked to infrastructure costs, cloud-provider dependence and AI safety. Individual stocks reflected renewed interest in AI infrastructure. Lumentum gained about 8% and Coherent rose around 6%, while Tesla advanced 5.2% after a Barclays upgrade. Meta Platforms fell 1.9% after announcing plans to raise up to $95 billion through equity offerings to fund its AI infrastructure expansion. The fundraising includes about $35 billion in public offerings and a separate share-sale programme of up to $60 billion. Meta's plans underscore investor scrutiny of the financing required to sustain AI-related capital expenditure. Economic data offered a mixed signal on US activity and price pressures. The Dallas Federal Reserve's general business activity index rose to 13.4 in October from 9.8 in September, exceeding the 8.8 consensus forecast. However, the production index fell to 15.8 from 29.5, and the new-orders index declined to 9.3 from 30.7. The survey also showed the raw-materials price index rising to 55.3 from 52.2, pointing to continued input-cost pressure. Powered by Capital Market - Live

Mankind Pharma Ltd share price inched up 3.83% to Rs 2302.0 after the company's net profit soared by 24.74% to Rs 716.12 crore, while revenue from operations slightly gained 7.62% to Rs 4337.86 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.54 lakh crore, gaining 3.38%. It has marginally improved by 0.07% over last one week and softened by 3.01% in last one month while the market capitalization of Mankind Pharma Ltd has improved by 2.22% and 11.20% in the same period respectively. Profit before tax (PBT) of Mankind Pharma Ltd stood at Rs 929.11 crore in Q3 FY26, surging by 48.89% year-on-year, and jumping 20.75% quarter-on-quarter. EBITDA came in at Rs 1076 crore, rallying 29.77% YoY and rising 6.45% sequentially. Total expenses saw a slight increase of 6.32% to Rs 3402.34 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 674.81 crore, marginally falling by 1.47% YoY, while employee benefits expense was at Rs 948.94 crore, inching up 3.88% YoY. For the TTM ended FY26, revenue from operations improved 16.96% to Rs 14277.64 crore, while net profit eased 3.41% to Rs 1938.1 crore, compared to previous TTM. EBITDA surged by 274510% to Rs 3258.62 crore, and PBT slipped by 7.30% to Rs 2332.68 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3121.29 crore in FY26, as against Rs 2413.38 crore in FY25. Mankind Pharma Ltd declined by 4.68% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.18% during the same period.

Mankind Pharma Ltd share price slipped 2.63% to Rs 2217.0. The Company's net profit jumped 24.74% to Rs 716.12 crore, while revenue from operations slightly gained 7.62% to Rs 4337.86 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.19 lakh crore, gaining 3.26%. It has eased by 1.73% over last one week and softened by 3.54% in last one month while the market capitalization of Mankind Pharma Ltd has softened by 1.55% and 15.31% in the same period respectively. Profit before tax (PBT) of Mankind Pharma Ltd stood at Rs 929.11 crore in Q3 FY26, surging by 48.89% year-on-year, and jumping 20.75% quarter-on-quarter. EBITDA came in at Rs 1076 crore, expanding by 29.77% YoY and easing 6.45% sequentially. Total expenses grew marginally by 6.32% to Rs 3402.34 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 674.81 crore, softening by 1.47% YoY, while employee benefits expense was at Rs 948.94 crore, inching up 3.88% YoY. For the TTM ended FY26, revenue from operations advanced 16.96% to Rs 14277.64 crore, while net profit eased 3.41% to Rs 1938.1 crore, compared to previous TTM. EBITDA soared by 274510% to Rs 3258.62 crore, and PBT dipped slightly 7.30% to Rs 2332.68 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 3121.29 crore in FY26, as against Rs 2413.38 crore in FY25. Mankind Pharma Ltd crashed 9.48% in last one year, outperforming the benchmark BSE Sensex which has declined by 13.52% during the same period.

Mankind Pharma Limited announced that it has paid interest and redemption amounts to holders of its Non-Convertible Debentures, INE634S07025 and INE634S07033, on October 16, 2026, as per Regulation 57(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company paid Rs 500,743,150 gross interest (Rs 499,741,677 net of taxes) on ISIN INE634S07025 and Rs 998,979,452 gross interest (Rs 998,579,873 net of taxes) on ISIN INE634S07033, and fully redeemed a total of 1,25,000 NCDs with a combined value of Rs 12,50,00,00,000.

Mankind Pharma announced it will acquire a 70% stake in Belgium-incorporated biotechnology company Armed Cell Therapeutics B.V. (ACTx) through its Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., for a consideration of EUR 48 million. The acquisition, part of Mankind Pharma’s strategy to build a global innovation-led pharmaceutical business, will be funded through an additional investment of up to EUR 45 million in Mankind Pharma (Netherlands) B.V., increasing the aggregate investment limit to EUR 50 million. ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer.

Mankind Pharma announced it will acquire a 70% stake in Belgium-incorporated biotechnology company Armed Cell Therapeutics B.V. (ACTx) through its Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., for a consideration of EUR 48 million. The acquisition, part of Mankind Pharma’s strategy to build a global innovation-led pharmaceutical business, will be funded through an additional investment of up to EUR 45 million in Mankind Pharma (Netherlands) B.V., bringing the total investment to EUR 50 million. ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer.

Mankind Pharma Limited informed the BSE Limited and National Stock Exchange of India Limited that KFin Technologies Limited, the company's Registrar to an Issue and Share Transfer Agent, confirmed that no requests for dematerialisation or rematerialisation of shares were received during the period from July 1, 2026, to September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Mankind Pharma Limited will hold a board meeting on October 26, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and the trading window will remain closed until October 28, 2026, as previously announced on September 25, 2026.

Mankind Pharma Limited will close its trading window for securities dealings from October 1, 2026, until 48 hours after the declaration of unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.